H1B Salary Data

Home › Employers › Gennao Bio Inc.

Gennao Bio Inc.: H-1B salaries and sponsorship

Gennao Bio Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $157,039.

Applications (LCAs)3
Certified3
Employer addressPennington, NJ
H-1B dependent employerNo
Median offered salary$157,039
Middle half of salaries$120,546–$164,034
10th–90th percentile$98,650–$168,232

Does Gennao Bio Inc. sponsor H-1B visas?

Gennao Bio Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Sep 11, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Senior Scientist Pharmacology1$157,039
Research Associate, Molecular Biology1$84,053
Senior Scientist (Molecular Biology)1$171,030

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20232$120,546
FY20241$171,030

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Senior Scientist (Molecular Biology)$171,030
Level IV
Pennington, NJSep 11, 2024Feb 28, 2025Certified
Research Associate, Molecular Biology$84,053–$95,000
Level III
Pennington, NJAug 22, 2023Oct 1, 2023Certified
Senior Scientist Pharmacology$157,039
Level IV
Pennington, NJApr 21, 2023Oct 1, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).